A Clinical Study of Cutaneous Adverse Reactions to Nonionic Contrast Media in Korea

Kyung Eun Jung, M.D., Jimin Chung, M.D.1, Byung Cheol Park, M.D.1, Keum Nahn Jee, M.D.2, Young Koo Jee, M.D.3, Myung Hwa Kim, M.D.1

Department of Dermatology, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Departments of 1Dermatology, 2Radiology, 3Internal Medicine, College of Medicine, Dankook University, Cheonan, Korea

Background: The use of intravenous contrast media (CM) has increased for the diagnosis of several diseases. The newly developed low osmolar nonionic contrast agents cause significantly decreased adverse reactions than the higher osmolar ones. However, adverse reactions may still occur, ranging in severity from minor side effects to severe complications. However, there have been few reports about cutaneous adverse reactions (CARs) to nonionic monomer CM. Objective: The purpose of this study was to evaluate clinical features of CAR to intravenous nonionic monomer CM. Methods: A total 47,338 examinees underwent intravenous iodinated contrast-enhanced computed tomography scan using nonionic monomer CM. Among the adverse reactions to the CM, we divided them into cutaneous or noncutaneous and immediate (< 1 hr) or late (≥ 1 hr) adverse reactions. Results: Adverse reactions were noted in 62 cases out of the total 47,338 cases; 50 cases (80.7%) were categorized CARs. Among them, there were 24 male and 26 female patients. There was no significant difference between the sexes, and CARs occurred in all age groups. The highest occurrence was in the age range of 50–59 years. CARs included urticaria (78%), angioedema (10%), maculopapular rash (8%), erythema (2%), and pruritus without rash (2%). Immediate reactions were 92% (46 cases), while late reactions were 8% (4 cases). Conclusion: CARs to nonionic monomer CM accounted for most of the adverse reactions (80.7%) and urticaria was the most common. (Ann Dermatol 24(1) 22~25, 2012)

-Keywords- Contrast media, CT, Cutaneous adverse reaction

INTRODUCTION

Imaging modality using contrast media (CM) is increasing. Adverse reactions to CM range from a mild inconvenience, such as nausea, vomiting, flushing, and pruritus, to life-threatening hypotension, anaphylactoid reaction, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The adverse reactions occurring after CM administration may be divided into three different types: allergic and non-allergic hypersensitivity reactions, toxic reactions and events unrelated to CM exposure. The CM maybe divided into higher osmolar, ionic agent and lower osmolar, nonionic agent. The former dissociate into ions when dissolved in water and are contained in an iodinated benzene ring. As a result, ionic agents have a higher osmolarity than blood, and the latter is less likely to cause adverse reaction. To date there has been research conducted on the adverse reactions of CM, but studies on cutaneous adverse reaction (CAR) are rare. Here, we report results for CARs due to nonionic monomer CM, and hope to provide useful data for patient care and clinical research.
MATERIALS AND METHODS

Materials

We studied 50 CAR cases that were reported by patients or perceived by computed tomography (CT) radiological staff using nonionic monomer CM for CT scan between August 2005 and November 2009. We investigated adverse reactions in nature and gender difference through medical records and telephone contacts. The CM that causes adverse reactions includes nonionic monomer including Iomeprol (Iomeron, Ilsung pharmaceuticals CO., Seoul, Korea), Iopamidol (Iopamiro, Ilsung pharmaceuticals CO.), Iopromide (Ultravist, Bayerin Korea), Ioversol (Optiray, Mallinckrodt, St. Louis, MO, USA).

Methods

1) Types and severity of adverse reactions of CM

The adverse reactions to nonionic monomer CM are classified into cutaneous, respiratory, cardiovascular, gastrointestinal symptoms. We defined the immediate reactions which occur within 1 hour after CM administration, and the delayed reactions which occur more than 1 hour after injection. The severity of the reaction was classified into mild and severe, and severe adverse reactions were defined as one or any combination of the following symptoms: dizziness, severe generalized urticaria, hypotension, laryngeal edema, and facial edema.

2) Statistics

The results of the study were analyzed statistically by chi square test using Statistical Package for the Social Sciences (SPSS) version 12.0 for Windows (SPSS Inc., Chicago, IL, USA). All statistical significance levels of differences were less than 0.05.

RESULTS

Adverse reactions and clinical manifestation

From August 2005 to November 2009, a total 47,338 examinees (27,733 male, 19,615 female) underwent intravenous iodinated contrast-enhanced CT scans using nonionic monomer CM. Age distribution varied from 0 to over 80 years. Of the total 47,338 examinees, 62 experienced adverse reactions. Among them, 50 cases (80.7%) were categorized into CARs. Other symptoms included dizziness (n=10), hypotension (n=6), vomiting (n=6), dyspnea (n=4), chest pain (n=3), headache (n=2), perspiration (n=2), rhinorrhea (n=1), nasal congestion (n=1), cough (n=1), palpitation (n=1), anxiety (n=1), chill (n=1), and nausea (n=1). Severe adverse reactions such as dizziness, severe generalized urticaria, hypotension, and facial edema occurred in 16 cases, which accounted for 25.8% of all 62 cases of adverse reactions.

General characteristics of CARs

CARs occurred in 24 men and 26 women, with an age range from 18 to 81 and the 50’s showed highest incidence, making the average age 51.5 (Table 1). On past medical history, a total of 17 cases of CAR combined with malignant neoplasm: colon cancer (n=6), stomach cancer (n=3), kidney cancer (n=3) and other cancer. Five allergic history including atopic dermatitis (n=2), food allergy (n=1), drug allergy (n=1) and chronic urticaria (n=1) was accompanied by CARs. Three of CAR patients had past previous history of contrast adverse reaction. Other than that, hypertension (n=13), diabetes mellitus (n=6), kidney disease (n=5), tuberculosis (n=3), liver cirrhosis (n=3), hepatitis (n=2) combined with CARs, and asthma.

Table 1. Age distribution of CARs to nonionic CM

| Age (yr) | Male (No) | Female (No) | Overall range (No) |
|---------|-----------|-------------|--------------------|
| 10~19   | 0         | 1           | 1                  |
| 20~29   | 1         | 3           | 4                  |
| 30~39   | 4         | 1           | 5                  |
| 40~49   | 2         | 6           | 8                  |
| 50~59   | 7         | 10          | 17                 |
| 60~69   | 4         | 4           | 8                  |
| 70~79   | 5         | 1           | 6                  |
| >80     | 1         | 0           | 1                  |
| Total   | 24        | 26          | 50                 |

CARs: cutaneous adverse reactions, CM: contrast media, No: number.

Table 2. Past medical history of the 50 patients with CARs to nonionic monomer CM

| Past medical history     | Number |
|--------------------------|--------|
| Malignant neoplasm       | 17     |
| Hypertension             | 13     |
| Diabetes Mellitus        | 6      |
| Allergic history         | 5      |
| Atopic dermatitis        | 2      |
| Food reaction            | 1      |
| Drug reaction            | 1      |
| Chronic urticaria        | 1      |
| Renal disease            | 5      |
| Past adverse reactions to CM | 3     |
| Tuberculosis             | 3      |
| Hepatitis                | 2      |
| Asthma                   | 0      |

CARs: cutaneous adverse reactions, CM: contrast media.
Table 3. Immediate and delayed CARs to nonionic monomer CM

|                      | Immediate No (%) | Delayed No (%) |
|----------------------|------------------|----------------|
| Urticaria            | 39 (78)          | 4 (8)          |
| Angioedema           | 5 (10)           |                |
| Erythema             | 1 (2)            |                |
| Pruritus without rash| 1 (2)            |                |
| Total                | 46 (92)          | 4 (8)          |

CARs: cutaneous adverse reactions, CM: contrast media, No: number.

was not included in those cases (Table 2).

CARs and clinical manifestation

Forty-six cases (92%) of CAR were immediate hypersensitivity reactions including 39 cases (78%) of urticaria, 5 cases (10%) of angioedema, 1 case (2%) of erythema, 1 case (2%) of pruritus without rash. Delayed type hypersensitivity accounted for 4 cases (8%), presenting maculopapular rash (Table 3).

Treatment and progress

Seven cases were resolved spontaneously, and some were resolved after oxygen infusion (n=1), hydration (n=10), oxygen and hydration (n=1), Pheniramine injection (n=16), oral antihistamine (n=2), Pheniramine and dexamethasone or dexamethasone alone (n=23), combining epinephrine (n=2).

DISCUSSION

In the past, we had frequent adverse reactions and poor radiographic imaging due to using hyperosmolar ionic CM. However, the adverse reaction decreased following the introduction of low osmolar CM, which was achieved by converting tri-iodinated benzoic acid into a nonionic molecule by replacing the carboxylic acid radical with an amide in the 1970s. Skin eruption was known as the most common adverse reaction of nonionic CM. In studies of Mortelé et al., among 545 hypersensitivity cases, 286 were urticaria, 131 were pruritus, 114 were rash, 7 were associated with severe responses. Therefore a total of 538 CARs (98.7% of all hypersensitivity reactions) were reported, which was higher than the result of current study (80.7%; 50 out of 62 cases).

There was no gender difference for CARs in this study, which was similar to the Wendt-Nordahl et al. result where they investigated CARs after using nonionic CM for intravenous urography.

Adverse hypersensitivity reactions mainly occurred in 20 to 50 year old patients, as like drug hypersensitivity reactions for they have vigorous immune function. In our study, incidence of CARs was higher for 20 to 50 year old patients than for other age groups (p<0.05).

Delayed-type hypersensitivity reactions have been reported ranging from 0.52% to 9%, because it is difficult to correlate the relationship between the symptoms and usage of CM after a certain amount of time has passed. More than 50% of the delayed type hypersensitivity reaction includes maculopapular rash, but because some include lethal responses such as Stevens-Johnson syndrome and toxic epidermal necrolysis, careful attention of the delayed type reaction is necessary after the use of CM even if there is no immediate hypersensitivity reaction. This study included 4 cases of maculopapular rash out of 47,338 cases which did not show immediate symptoms, therefore the patient may not have recognized it as a hypersensitivity reaction caused by CM, and because the mild symptoms resolved spontaneously it may have been missed from the record.

The pathogenesis of hypersensitivity caused by CM is known to be related to drug reactions or non-immunologic mechanisms. Immediate type was proved to be related to histamines from mast cells by Laroche et al., and that IgE related responses may explain the pathogenesis of contrast hypersensitivity. The delayed type is clinically similar to the T-cell mediated drug eruption, and by looking at lymphocytic infiltrations after the biopsy of skin lesions, skin reaction tests and patch tests, the relationship between the reaction and T-cell is now recognized. Still, the exact pathogenesis of hypersensitivity caused by CM is not known, and therefore further study is needed to prove it.

There is a report that shows the hypersensitivity caused by CM can be reduced by using corticosteroid prior to the use of CM by Lasser et al. and Greenberger et al. On the other hand, Wolf et al. suggested that the use of corticosteroid to reduce the rate of hypersensitivity caused by CM is not yet proven. However, when the patient has prior history of systemic hypersensitivity to CM and when it is not in a very urgent state, using the steroid before CM infusion may help in reducing the hypersensitivity of CM, provided the patient is not in a contraindication state of using the steroid.

In Conclusion, Based on 50 cases of CARs to nonionic CM from August 2005 to November 2009, we have come to the following conclusion: there was no difference between the sexes. The incidence of CARs was higher among people in their 20’s to 50’s than for other ages, because their immune system function is more active than at other ages, and among them the 50’s showed highest incidence of hypersensitivity. Three among 50 people
who showed CAR had previous adverse reaction to contrast material. CARs included 39 cases of urticaria (78%), 5 cases of angioedema (10%), 4 cases of maculopapular rash (8%), 1 case of erythema (2%), 1 case of pruritus (2%). A total of 46 cases (92%) showed immediate type reaction, while 4 cases (8%) showed delayed type reactions, presenting as maculopapular rash. Because the study is retrograded in finding CARs among delayed type reactions, presenting as maculopapular rash. immediate type reaction, while 4 cases (8%) showed of pruritus (2%). A total of 46 cases (92%) showed maculopapular rash (8%), 1 case of erythema (2%), 1 case (78%), 5 cases of angioedema (10%), 4 cases of contrast material. CARs included 39 cases of urticaria who showed CAR had previous adverse reaction to because the result was reported via patients themselves and medical team in CT room, some patients such as those who had mild symptoms may have been excluded from the study. Therefore, in order to measure and analyze CAR due to CM more accurately, an anterograde study at a large scale is mandatory.

REFERENCES

1. Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991;157:1153-1161.
2. Christiansen C, Pichler WJ, Scotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000;10:1965-1975.
3. Brockow K, Christiansen C, Kanny G, Clément O, Barbad A, Bircher A, et al; ENDA; EAACI interest group on drug hypersensitivity. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005;60:150-158.
4. Maddox TG. Adverse reactions to contrast material: recognition, prevention, and treatment. Am Fam Physician 2002;66:1229-1234.
5. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990;175:621-628.
6. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001;176:1385-1388.
7. Mortelé Kj, Oliva MR, Ondategui S, Ros PR, Silverman SG. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am J Roentgenol 2005;184:31-34.
8. Wang CL, Cohan RH, Ellis JH, Cailli EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2001;180:409-415.
9. Meth MJ, Maibach Hl. Current understanding of contrast media reactions and implications for clinical management. Drug Saf 2006;29:133-141.
10. Kim SS, Park CH, Park MJ, Choi SH, Kim YS, Park HW, et al. Adverse reactions to radio-contrast media in computed tomography (CT) in general population: incidence and clinical features. Korean J Asthma Allergy Clin Immunol 2007; 27:157-161.
11. Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001;11:1267-1275.
12. Wendt-Nordahl G, Rotert H, Trojan L, Michel MS, Peters CR, Alikin P, et al. Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients. Med Princ Pract 2006;15:358-361.
13. Pedersen SH, Svaland MG, Reiss AL, Andrew E. Late allergy-like reactions following vascular administration of radiography contrast media. Acta Radiol 1998;39:344-348.
14. Hosoya T, Yamaguchi K, Akutsu T, Mitsushashi Y, Kondo S, Sugai Y, et al. Delayed adverse reactions to iodinated contrast media and their risk factors. Radiat Med 2000;18:39-45.
15. Yoshikawa H. Late adverse reactions to nonionic contrast media. Radiology 1992;183:737-740.
16. Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gérard P, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 1998;209:183-190.
17. Mita H, Tadokoro K, Akiyama K. Detection of IgE antibody to a radiocontrast medium. Allergy 1998;53:1133-1140.
18. Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period. Clin Exp Allergy 2006;36:1072-1077.
19. Brockow K, Becker EW, Woret W, Ring J. Late skin test reactions to radiocontrast medium. J Allergy Clin Immunol 1999;104:1107-1108.
20. Delgado-Jimenez Y, Perez-Gala S, Aragués M, Sanchez-Perez J, Garcia-Diez A. Late skin reaction to iodixanol (Visipaque): clinical manifestations, patch test study, and histopathological evaluation. Contact Dermatitiss 2006;55:348-353.
21. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol 2005;115:179-185.
22. Lasser EC, Berry CC, Talner LB, Santini LC, LangEK, Gerber FH, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987;317:845-849.
23. Greenberger P, Patterson R, Kelly J, Stevenson DD, Simon D, Lieberman P. Administration of radiographic contrast media in high-risk patients. Invest Radiol 1980;15(Suppl): S40-43.
24. Wolf GL, Mishkin MM, Roux SG, Halpern EF, Gottlieb J, Zimmerman J, et al. Comparison of the rates of adverse drug reactions. Ionic contrast agents, ionic agents combined with steroids, and nonionic agents. Invest Radiol 1991;26:404-410.
25. Thomsen HS, Bush WH Jr. Adverse effects of contrast media: incidence, prevention and management. Drug Saf 1998;19:313-324.
26. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. AJR Am J Roentgenol 1994;162:523-526.
27. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991;87:867-872.